Dimitris Voliotis - Net Worth and Insider Trading
Dimitris Voliotis Net Worth
The estimated net worth of Dimitris Voliotis is at least $63,273 dollars as of 2024-11-10. Dimitris Voliotis is the SVP, Clinical Development of Zentalis Pharmaceuticals Inc and owns about 15,978 shares of Zentalis Pharmaceuticals Inc (ZNTL) stock worth over $63,273. Details can be seen in Dimitris Voliotis's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Dimitris Voliotis has not made any transactions after 2022-02-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Dimitris Voliotis
Dimitris Voliotis Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Dimitris Voliotis owns 1 companies in total, including Zentalis Pharmaceuticals Inc (ZNTL) .
Click here to see the complete history of Dimitris Voliotis’s form 4 insider trades.
Insider Ownership Summary of Dimitris Voliotis
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals Inc | 2022-02-14 | SVP & Clinical Development |
Dimitris Voliotis Latest Holdings Summary
Dimitris Voliotis currently owns a total of 1 stock. Dimitris Voliotis owns 15,978 shares of Zentalis Pharmaceuticals Inc (ZNTL) as of February 14, 2022, with a value of $63,273.
Latest Holdings of Dimitris Voliotis
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals Inc | 2022-02-14 | 15,978 | 3.96 | 63,273 |
Holding Weightings of Dimitris Voliotis
Dimitris Voliotis Form 4 Trading Tracker
According to the SEC Form 4 filings, Dimitris Voliotis has made a total of 2 transactions in Zentalis Pharmaceuticals Inc (ZNTL) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Zentalis Pharmaceuticals Inc is the sale of 601 shares on February 14, 2022, which brought Dimitris Voliotis around $30,188.
Insider Trading History of Dimitris Voliotis
- 1
Dimitris Voliotis Trading Performance
Dimitris Voliotis Ownership Network
Ownership Network List of Dimitris Voliotis
Ownership Network Relation of Dimitris Voliotis
Dimitris Voliotis Owned Company Details
What does Zentalis Pharmaceuticals Inc do?
Who are the key executives at Zentalis Pharmaceuticals Inc?
Dimitris Voliotis is the SVP & Clinical Development of Zentalis Pharmaceuticals Inc. Other key executives at Zentalis Pharmaceuticals Inc include Chief Financial Officer Melissa B, Epperly , General Counsel Andrea Paul , and Chief Medical Officer Carrie Brownstein .
Zentalis Pharmaceuticals Inc (ZNTL) Insider Trades Summary
Over the past 18 months, Dimitris Voliotis made no insider transaction in Zentalis Pharmaceuticals Inc (ZNTL). Other recent insider transactions involving Zentalis Pharmaceuticals Inc (ZNTL) include a net sale of 50,090 shares made by Cam Gallagher , a net sale of 16,724 shares made by Melissa B, Epperly , and a net sale of 86,068 shares made by Kevin D. Bunker .
In summary, during the past 3 months, insiders sold 1,603 shares of Zentalis Pharmaceuticals Inc (ZNTL) in total and bought 0 shares, with a net sale of 1,603 shares. During the past 18 months, 178,364 shares of Zentalis Pharmaceuticals Inc (ZNTL) were sold and 22,000 shares were bought by its insiders, resulting in a net sale of 156,364 shares.
Zentalis Pharmaceuticals Inc (ZNTL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Zentalis Pharmaceuticals Inc Insider Transactions
Dimitris Voliotis Mailing Address
Above is the net worth, insider trading, and ownership report for Dimitris Voliotis. You might contact Dimitris Voliotis via mailing address: C/o Zentalis Pharmaceuticals, Inc., 530 Seventh Avenue, Suite 2201, New York Ny 10018.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
